Key clinical point: Molecularly guided treatments may significantly extend survival for patients with pancreatic cancer.
Major finding: Patients with pancreatic cancer and actionable molecular alterations who received a matched therapy had significantly longer median overall survival compared with patients who had actionable alterations and did not receive a matched therapy (2.58 vs. 1.51 years; P = .0004).
Study details: A retrospective study of 1,856 patients with pancreatic cancer in the Know Your Tumor registry.
Disclosures: The study was funded by Pancreatic Cancer Action Network and Perthera. The investigators disclosed relationships with Perthera and other companies.
Pishvaian MJ et al. Lancet Oncol. 2020 Mar 2. doi: 10.1016/S1470-2045(20)30074-7.